YOLFTbeta
Incannex Healthcare Inc.

Incannex Healthcare Inc.

IXHL · NASDAQ · Healthcare / Drug Manufacturers - Specialty & Generic

1.97USD-0.05 (-2.48%)

Price History

Full chart

Market Stats

Previous Close2.02
Open1.98
Day Range1.91 – 2.07
52-Week Range2.49 – 15.00
Volume100.22K
Market Cap41.65M
P/E (TTM)0.00
Forward P/E3.78
EPS-1.66
Dividend Yield0.00%
Beta2.83
50-Day Avg3.29
200-Day Avg5.38

About

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Joel Bradley Latham
  • Employees12
  • Headquarters8 Century Circuit, Sydney, NSW, Australia, 2153, USA
  • Websitehttps://www.incannex.com

Leadership

  • Mr. Joel Bradley LathamPresident, CEO & Executive Director · b. 1989
  • Mr. Joseph SwanCFO, Treasurer & Secretary · b. 1991
  • Dr. Luigi M. Barbato M.D.Chief Medical Officer
  • Mr. Lekhram Changoer M.Sc.CTO & Member of Advisory Board · b. 1967
  • Dr. Mark Bleackley Ph.D.Chief Scientific Officer, Head of Programs & Member of the Advisory Board
  • Mr. John Michailidis B.Sc., EMBA, M.A.I.C.D.Chief Executive Officer of IncannexTM
  • Natalie MayHead of Clinical Operations

Financials

Income Statement

Currency: AUD2006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue----26.37K-67.05K35.25K--91.69K283.01K1.01M1.18M599.72K1.90M785.15K1.01M12.00K86.00K-
Growth (%)--------47.43%---+208.67%+256.81%+16.90%-49.20%+216.41%-58.62%+29.13%-98.82%+616.67%-
Cost of Revenue20.70K---391.01K39.00K1.20M819.30K457.77K18.09K303.33K518.27K522.83K583.19K446.50K911.97K6.33K88.08K103.00K246.00K240.00K
Gross Profit-20.70K---26.37K-39.00K-1.20M35.25K-457.77K-18.09K-213.89K-235.26K486.99K597.26K153.22K985.63K778.79K-88.08K12.00K-160.00K-240.00K
Gross Margin----100.00%--1792.19%100.00%---233.28%-83.13%48.23%50.60%25.55%51.94%99.19%-8.69%100.00%-186.05%-
Operating Expense178.41K---1.92M2.69M2.17M10.84M6.23M2.50M444.16K20.79M3.70M3.39M4.26M9.22M12.13M20.44M30.05M23.63M22.79M
Operating Income-199.11K-1.07M-1.34M-2.98M-1.90M-2.73M-3.37M-10.80M-6.68M-2.52M-658.05K-21.03M-3.21M-2.79M-4.11M-8.24M-11.35M-20.53M-30.04M-23.79M-23.03M
Operating Margin-----7196.36%--5028.19%-30643.48%---717.71%-7429.94%-317.91%-236.59%-685.50%-434.20%-1445.67%-2024.57%-250341.67%-27661.63%-
EBITDA-220.78K-1.04M-1.04M-3.83M2.72M-4.49M-3.21M-12.71M-13.19M-2.53M-704.75K-20.99M-3.14M-2.75M-4.06M-8.16M-16.54M-20.39M-27.70M-23.54M-23.03M
EBITDA Margin----10330.05%--4781.34%-36063.18%---768.64%-7415.65%-310.58%-232.74%-676.70%-430.21%-2107.04%-2011.50%-230852.82%-27375.58%-
Net Income-242.46K-982.54K-1.10M-3.91M2.55M-4.62M-3.19M-13.36M-11.96M-2.56M-719.93K-20.76M-2.94M-2.72M-4.66M-8.16M-14.90M-73.47M-18.46M-46.88M-19.30M
Net Income Margin----9667.34%--4757.45%-37900.73%---785.20%-7336.22%-291.24%-230.67%-776.62%-430.07%-1898.02%-7246.01%-153825.00%-54517.44%-
R&D-------------516.81K1.46M4.65M5.37M9.50M19.28M10.75M5.21M
R&D as % of Total Revenue-------------43.78%242.88%244.81%684.10%936.57%160676.25%12496.51%-
Interest Expense21.11K6.43K12.18K48.17K123.09K94.93K191.13K188.02K174.43K120.84K81.50K49.97K12.85K85.21K89.82.68K218.073.01K-303.00K-
Interest Expense % of Total Revenue----466.75%-285.04%533.38%--88.89%17.66%1.27%7.22%0.01%0.14%0.03%0.30%-352.33%-

Balance Sheet

Currency: USD2006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets1.68M6.82M10.58M14.81M16.05M20.10M24.08M19.18M7.77M6.30M344.94K1.00M711.51K520.05K2.91M7.01M38.01M35.80M17.05M20.45M72.98M
Total Liabilities343.08K173.25K1.07M8.23M3.77M4.87M3.98M5.63M6.03M5.82M1.05M1.17M1.10M938.95K736.35K567.30K2.02M4.45M5.83M7.06M5.61M
Total Equity1.34M6.64M9.51M6.58M12.29M15.23M20.10M13.55M1.74M478.47K-700.36K-169.45K-385.29K-418.90K2.17M6.44M36.00M31.34M11.22M13.39M67.37M
Cash-4.15M1.08M42.21K533.45K750.75K561.61K509.65K397.52K177.80K4.57K508.74K229.58K93.72K2.48M6.85M37.50M33.29M5.86M15.04M67.71M
Total Debt300.04K80.39K106.26K6.55M1.90M1.00M1.13M1.68M1.26M1.00M698.88K398.89K201.03K65.27K---784.16K373.00K258.00K96.00K
Net Debt300.04K-4.07M-974.62K6.51M1.36M250.12K568.31K1.17M864.47K826.17K694.30K-109.85K-28.55K-28.45K-2.48M-6.85M-37.63M-32.51M-5.49M-14.78M-67.61M

Cash Flow

Currency: USD2006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Operating Cash Flow-79.83K-371.63K-2.16M-1.80M-1.75M-2.97M-6.71M-4.80M390.60K-1.29M-643.93K-2.70M-3.00M-2.21M-3.89M-6.87M-12.85M-16.18M-15.85M-12.51M-12.87M
Investing Cash Flow-160.72K-58.07K-1.52M-260.42K-6.31K-3.41M-1.08M-200.15K-18.68K13.71K-188.05K3.02M-50.08K-24.54K12.89K29.32K-476.87K-475.61K-277.00K-8.00K-94.00K
Financing Cash Flow339.49K4.52M73.85K1.20M3.30M5.65M7.60M4.96M-487.77K1.03M835.90K183.18K2.76M2.10M7.37M12.33M41.18M12.30M021.40M65.90M
Capital Expenditure64228.84K62.64K23.40K6.31K2.03M1.11M198.82K18.68K3.81K9.29K50.30K50.09K24.54K476.87K4.155.23475.61K277.00K8.00K10.00K
Free Cash Flow-80.47K-372.59K-2.22M-1.67M-1.75M-4.99M-7.83M-5.00M371.92K-1.29M-653.23K-2.75M-3.05M-2.19M-3.89M-6.91M-12.85M-16.65M-16.12M-12.52M-12.88M
Dividends Paid-----1.37M----------00---
FCF to OCF100.80%100.26%102.91%92.51%100.36%168.27%116.59%104.14%95.22%100.30%101.44%101.87%101.67%99.26%100.00%100.56%100.00%102.94%101.75%100.06%100.08%
Dividend Paid to FCF------27.43%----------0.00%0.00%---

Earnings

Report DateSep 30, 2022Dec 31, 2022Sep 30, 2023Feb 26, 2024Mar 31, 2024Jun 30, 2024Nov 14, 2024Feb 14, 2025May 15, 2025Sep 29, 2025Nov 14, 2025Feb 13, 2026May 15, 2026Sep 25, 2026Nov 13, 2026
EPS Estimate-------21.48-20.43-0.46-0.45-18.09-0.93-0.840.13-0.01
EPS Actual-0.10-0.01-0.00-0.33-0.38-0.41-13.41-15.56-0.24-0.78-0.92-0.85-0.49-0.14-
Surprise------37.57%23.84%47.83%-73.33%94.91%8.60%41.67%-207.69%-
Timing---Pre-market--After-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-market-

Key Statistics & Ratios

Market Cap41.65M
Enterprise Value-33.06M
Trailing P/E0.00
Forward P/E3.78
Price / Sales84.20
Price / Book0.55
EPS-1.66
Book Value5.50
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-18.13M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-47.80%
Return on Assets-24.58%
Shares Outstanding12.54M
Shares Float10.06M
Beta2.83
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
3.81%
Insiders
12.34%
Retail / Other
83.85%

Top Institutional Holders

  • Polar Asset Management Partners
    625.00K5.22%
  • Ghisallo Capital Management LLC
    162.85K1.36%
  • MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.
    149.86K1.25%
  • Murchinson Ltd.
    104.11K0.87%
  • Millennium Management LLC
    95.25K0.80%
  • LPL Financial Corp
    71.18K0.59%
  • AdvisorShares Investments, LLC
    60.87K0.51%
  • UBS Group AG
    40.37K0.34%
  • Virtu Financial LLC
    16.16K0.14%
  • Commonwealth Equity Services, LLC
    14.03K0.12%
  • Citadel Advisors Llc
    10.35K0.09%
  • Advisor Group Holdings, Inc.
    6.38K0.05%
  • Morgan Stanley - Brokerage Accounts
    2.06K0.02%
  • Quent Capital, LLC
    1.93K0.02%
  • JPMorgan Chase & Co
    8250.01%
  • Barclays PLC
    7500.01%

Top Fund Holders

  • AdvisorShares Psychedelics ETF
    72.86K0.58%
  • Abante Quant Value FI
    43.27K0.34%
  • Fidelity Nasdaq Composite Index
    8.64K0.07%
  • JHVIT Total Stock Market Index I
    2430.00%

Stock Splits

  • Feb 27, 20261:30